Menten Biotechnology Labs - also known as Menten AI - is a company that develops new protein therapeutics for drug development through the use of machine learning and quantum computing. It was founded in 2018 by Hans Melo, Vikram Mulligan, and Tamas Gorbe. Menten Biotechnology Labs is headquartered in San Francisco, California, United States. It has received funding from investors such as Uncork Capital, Founders X, and Khosla Ventures. Menten Biotechnology was a cohort of Y Combinator's W20.
Menten Biotechnology Labs leverages machine learning (in the form of Rosetta) and quantum computing (in the form of D-Wave) capabilities to design and modify proteins. These newly generated proteins are meant to be used for drug development purposes, though it can also be used for manufacturing processes. The company's approach is meant to address the current approach, where new protein structures are generated through random trials instead of intentional designs.